Non-Hodgkin Lymphoma
News
CHMP recommends conditional approval of drug for CLL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of venetoclax (Venclyxto™)....
Conference Coverage
Speaker outlines importance of cell of origin in DLBCL
NEW YORK—The importance of cell of origin in choosing a treatment for diffuse large B-cell lymphoma (DLBCL) is a topic “that has been kicking...
News
Drug granted conditional approval to treat CLL in Canada
of venetoclax (Venclexta) Photo courtesy of AbbVie Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for the BCL-2...
News
Enzyme may be therapeutic target for NHL
telomeres in green Image by Claus Azzalin New research indicates that an enzyme called uracil-DNA glycosylase (UNG) protects the ends of B-cell...
News
KTE-C19 produces responses in aggressive NHL
Interim results of a phase 1/2 trial suggest KTE-C19, a chimeric antigen receptor (CAR) T-cell therapy, can be effective against aggressive non-...
News
Cancer report details progress, predicts problems
Photo by Rhoda Baer A new report highlights recent advances made in the fight against cancer but suggests the burden of cancer in the US is still...
News
Drug granted fast track designation for MF
mycosis fungoides The US Food and Drug Administration (FDA) has granted fast track designation to Resimmune® (A-dmDT390-bisFv[UCHT1]) for the...
News
Optimizing CAR T-cell therapy in NHL
Photo from Fred Hutchinson Cancer Research Center Results from a phase 1 study have provided insights that may help researchers optimize treatment...
News
Risk factors for early death in older pts with DLBCL
Photo courtesy of CDC A retrospective study has uncovered potential risk factors for early death in older patients with diffuse large B-cell...
News
FDA approves new indication for ofatumumab in CLL
Photo courtesy of GSK The US Food and Drug Administration (FDA) has approved the use of ofatumumab (Arzerra®) in combination with fludarabine and...
News
FDA grants drug orphan designation for CLL
The US Food and Drug Administration (FDA) has granted orphan drug designation to the PI3K delta inhibitor TGR-1202 for the treatment of chronic...